Hims & Hers Health Inc Stock Price, News & Analysis

Hims & Hers Health (NYSE: HIMS) has announced plans to offer $450 million in convertible senior notes due 2030, with an additional option for purchasers to buy up to $67.5 million. The notes will be offered privately to qualified institutional buyers under Rule 144A. The proceeds will fund the company's global expansion initiatives, both through organic growth and potential strategic acquisitions, though no definitive agreements are currently in place. Additionally, the funds will support enhanced AI development, data pipeline expansion, and advancement of personalized treatments under new CTO Mo Elshenawy. The notes will be senior, unsecured obligations with semi-annual interest payments, convertible under certain conditions into cash, Class A common stock, or a combination thereof. The company plans to enter into capped call transactions to reduce potential dilution and offset potential cash payments above the principal amount.

Hims & Hers Health (NYSE: HIMS) has appointed Mo Elshenawy as its new Chief Technology Officer, marking a significant step in the company's AI-driven healthcare vision. Elshenawy, former President and CTO at Cruise, brings over 20 years of technology sector experience, including expertise in AI, product development, and engineering.

At Cruise, he led the launch of the first commercial driverless rideshare service in San Francisco. His previous experience includes senior leadership roles at Amazon, where he managed global engineering for ReCommerce and developed retail data analytics platforms. Elshenawy holds more than 10 patents in AI, robotics, and autonomous vehicles.

The appointment aligns with Hims & Hers' strategy to build a next-generation healthcare platform powered by AI, focusing on personalized care delivery at scale. The company plans to expand its MedMatch system and invest in AI to enhance diagnosis and improve health and wellness experiences.

Hims & Hers Health (NYSE: HIMS) reported exceptional Q1 2025 financial results, with revenue surging 111% year-over-year to $586.0 million. The company achieved net income of $49.5 million and Adjusted EBITDA of $91.1 million. Subscriber base grew 38% YoY to 2.4 million, with monthly online revenue per average subscriber increasing 53% to $84.

The company maintained its 2025 revenue guidance of $2.3-2.4 billion and raised Adjusted EBITDA guidance to $295-335 million. Notably, Hims & Hers introduced ambitious 2030 targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA. For Q2 2025, the company expects revenue of $530-550 million and Adjusted EBITDA of $65-75 million.

Hims & Hers Health (NYSE: HIMS) has appointed Nader Kabbani as Chief Operations Officer. Kabbani brings nearly 20 years of experience from Amazon, where he led significant initiatives including the PillPack acquisition, Amazon Pharmacy launch, and development of Amazon Logistics. He also managed Amazon's global COVID-19 Vaccination Task Force and held executive roles at Flexport and Symbotic.

As COO, Kabbani will oversee operations as Hims & Hers expands its health and wellness platform to provide personalized care to more individuals. His appointment strengthens the company's leadership team as it focuses on building infrastructure to scale access to affordable, seamless healthcare services.

Novo Nordisk and Hims & Hers have announced a groundbreaking collaboration to make obesity care more accessible and affordable in the United States. The partnership's first initiative introduces Wegovy through the Hims & Hers platform, bundled with comprehensive healthcare services.

The offering, priced at $599 per month, includes:

• All dose strengths of Wegovy
• 24/7 care access
• Ongoing clinical support
• Nutrition guidance
• Hims & Hers membership

Patients can now access NovoCare Pharmacy directly through the Hims & Hers platform. This collaboration combines Novo Nordisk's innovative treatments with Hims & Hers' scalable healthcare delivery system. The partnership aims to improve long-term outcomes for people living with obesity while maintaining affordability. The platform will continue offering additional weight loss solutions, including oral medications, protein supplements, nutrition kits, and clinically-backed care plans.

Hims & Hers Health (NYSE: HIMS) has scheduled the release of its first quarter 2025 financial results for Monday, May 5, 2025, after market close. The health and wellness platform will host a conference call at 5:00 p.m. ET to discuss the results.

Investors can join the conference call via telephone using (888) 510-2630 for U.S. participants or (646) 960-0137 for international participants, with conference ID 1704296. A live audio webcast will be available on the company's investor relations website and archived for one year.

Additionally, the company's management team will participate in the J.P. Morgan Global Technology, Media and Communications Conference on May 15, 2025, in Boston.

Define Ventures, a major early-stage health tech venture capital firm, has appointed Carolyn Magill as venture partner. Magill brings 25 years of experience in healthcare, having served as CEO of Aetion and Remedy Partners, and held executive positions at Evolent Health and UnitedHealth Group.

Magill joins existing venture partners Bruce Broussard (former Humana CEO) and Frank Williams (Evolent Health co-founder) to support Define's portfolio companies. The firm, managing $800 million in assets, invests in seed to series B stage companies and has backed notable ventures like Hims & Hers.

Her expertise spans payer, provider, and pharmaceutical sectors, with particular focus on data and AI applications. At Aetion, she led a platform transforming real-world data into regulatory-grade evidence, while at Remedy Partners she oversaw bundled payments software and services.

Hims & Hers Health (NYSE: HIMS) reported strong financial results for Q4 and full year 2024. The company achieved revenue of $1.5 billion in 2024, representing a 69% year-over-year increase, with net income of $126 million and Adjusted EBITDA of $177 million.

Subscriber base grew to 2.2 million, up 45% year-over-year. Revenue excluding GLP-1 offering increased 43% to over $1.2 billion. For Q4 2024, revenue was $481.1 million, up 95% from Q4 2023, with net income of $26 million.

The company provided guidance for 2025, projecting revenue between $2.3-2.4 billion and Adjusted EBITDA of $270-320 million. For Q1 2025, revenue is expected to be $520-540 million with Adjusted EBITDA of $55-65 million.

Hims & Hers Health has acquired a US-based peptide facility in California, strengthening its domestic supply chain capabilities. This acquisition follows previous purchases of 503A and 503B facilities, further verticalizing the company's operations. The move aims to enhance the company's ability to deliver personalized medications and meet growing demand from American consumers.

The peptide facility acquisition positions Hims & Hers to explore future innovations in areas including preventive health, metabolic optimization, cognitive performance, recovery science, and biological resistances. The transaction, which closed in early February, demonstrates the company's commitment to maintaining US-based operations for better control over cost, availability, and quality standards.